Toll Free: 1-888-928-9744

Neuroblastoma - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 383 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neuroblastoma - Pipeline Review, H1 2016


Global Markets Direct's, 'Neuroblastoma - Pipeline Review, H1 2016', provides an overview of the Neuroblastoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
- The report reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Neuroblastoma therapeutics and enlists all their major and minor projects
- The report assesses Neuroblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Neuroblastoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 6 Neuroblastoma Overview 7 Therapeutics Development 8 Neuroblastoma - Therapeutics under Development by Companies 10 Neuroblastoma - Therapeutics under Investigation by Universities/Institutes 14 Neuroblastoma - Pipeline Products Glance 16 Neuroblastoma - Products under Development by Companies 19 Neuroblastoma - Products under Investigation by Universities/Institutes 24 Neuroblastoma - Companies Involved in Therapeutics Development 25 Neuroblastoma - Therapeutics Assessment 71 Drug Profiles 87 Neuroblastoma - Recent Pipeline Updates 263 Neuroblastoma - Dormant Projects 360 Neuroblastoma - Discontinued Products 363 Neuroblastoma - Product Development Milestones 364 Appendix 371
List of Tables
Number of Products under Development for Neuroblastoma, H1 2016 19 Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2016 20 Number of Products under Development by Companies, H1 2016 21 Number of Products under Development by Companies, H1 2016 (Contd..1) 22 Number of Products under Development by Companies, H1 2016 (Contd..2) 23 Number of Products under Development by Companies, H1 2016 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H1 2016 26 Comparative Analysis by Late Stage Development, H1 2016 27 Comparative Analysis by Clinical Stage Development, H1 2016 28 Comparative Analysis by Early Stage Development, H1 2016 29 Products under Development by Companies, H1 2016 30 Products under Development by Companies, H1 2016 (Contd..1) 31 Products under Development by Companies, H1 2016 (Contd..2) 32 Products under Development by Companies, H1 2016 (Contd..3) 33 Products under Development by Companies, H1 2016 (Contd..4) 34 Products under Investigation by Universities/Institutes, H1 2016 35 Neuroblastoma - Pipeline by Ability Pharmaceuticals, S.L., H1 2016 36 Neuroblastoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 37 Neuroblastoma - Pipeline by Advanced Accelerator Applications S.A., H1 2016 38 Neuroblastoma - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 39 Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2016 40 Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2016 41 Neuroblastoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 42 Neuroblastoma - Pipeline by Bexion Pharmaceuticals, LLC., H1 2016 43 Neuroblastoma - Pipeline by BioLineRx, Ltd., H1 2016 44 Neuroblastoma - Pipeline by Bionucleon Srl, H1 2016 45 Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H1 2016 46 Neuroblastoma - Pipeline by Cebiotex, S.L., H1 2016 47 Neuroblastoma - Pipeline by Celgene Corporation, H1 2016 48 Neuroblastoma - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 49 Neuroblastoma - Pipeline by Cleveland BioLabs, Inc., H1 2016 50 Neuroblastoma - Pipeline by CorMedix Inc., H1 2016 51 Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 52 Neuroblastoma - Pipeline by DEKK-TEC, Inc., H1 2016 53 Neuroblastoma - Pipeline by EnGeneIC Ltd, H1 2016 54 Neuroblastoma - Pipeline by Errant Gene Therapeutics, LLC, H1 2016 55 Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 56 Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H1 2016 57 Neuroblastoma - Pipeline by Green Cross Cell Corporation, H1 2016 58 Neuroblastoma - Pipeline by Ignyta, Inc., H1 2016 59 Neuroblastoma - Pipeline by Incuron, LLC, H1 2016 60 Neuroblastoma - Pipeline by Juno Therapeutics Inc., H1 2016 61 Neuroblastoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 62 Neuroblastoma - Pipeline by Lindis Biotech GmbH, H1 2016 63 Neuroblastoma - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 64 Neuroblastoma - Pipeline by MediaPharma s.r.l., H1 2016 65 Neuroblastoma - Pipeline by MEI Pharma, Inc., H1 2016 66 Neuroblastoma - Pipeline by Merck & Co., Inc., H1 2016 67 Neuroblastoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 68 Neuroblastoma - Pipeline by Morphogenesis, Inc., H1 2016 69 Neuroblastoma - Pipeline by Novartis AG, H1 2016 70 Neuroblastoma - Pipeline by Novogen Limited, H1 2016 71 Neuroblastoma - Pipeline by Pfizer Inc., H1 2016 72 Neuroblastoma - Pipeline by Pharmacyclics, Inc., H1 2016 73 Neuroblastoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016 74 Neuroblastoma - Pipeline by Recombio S.L, H1 2016 75 Neuroblastoma - Pipeline by Ribomic Inc., H1 2016 76 Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2016 77 Neuroblastoma - Pipeline by Shionogi & Co., Ltd., H1 2016 78 Neuroblastoma - Pipeline by Syros Pharmaceuticals, Inc., H1 2016 79 Neuroblastoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 80 Neuroblastoma - Pipeline by Tiltan Pharma Ltd., H1 2016 81 Assessment by Monotherapy Products, H1 2016 82 Assessment by Combination Products, H1 2016 83 Number of Products by Stage and Target, H1 2016 85 Number of Products by Stage and Mechanism of Action, H1 2016 91 Number of Products by Stage and Route of Administration, H1 2016 95 Number of Products by Stage and Molecule Type, H1 2016 97 Neuroblastoma Therapeutics - Recent Pipeline Updates, H1 2016 274 Neuroblastoma - Dormant Projects, H1 2016 371 Neuroblastoma - Dormant Projects (Contd..1), H1 2016 372 Neuroblastoma - Dormant Projects (Contd..2), H1 2016 373 Neuroblastoma - Discontinued Products, H1 2016 374

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.